ReviewThe EMBO journal2026
The expanding roles of homologous recombination proteins in genome stability.
Review in The EMBO journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Distinct functions of mammalian RAD51 paralogs in genome maintenance.Biochemical Society transactions · 2026Review
- DNA damage response inhibitors in pancreatic cancer: progress and challenges.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Homologous recombination (HR) is traditionally portrayed as a DNA double-strand break repair pathway. However, emerging evidence positions RAD51, its partners BRCA1, BRCA2, and other HR factors at the core of a broader genome-maintenance network that operates by a "prevent and protect" strategy extending beyond repair. Here, we review how RAD51 can shield DNA from nucleolytic processing mediated by MRE11 and related nucleases, promote fork reversal, suppress replicative DNA gaps accumulation, and bind abasic sites, averting their conversion into cytotoxic intermediates. These extended functions counteract endogenous replication stress as shown in BRCA1- or BRCA2-deficient contexts, where failure to prevent gaps, protect forks, and safeguard abasic DNA accelerates genomic instability. The functional impairment of HR proteins, which interface with base-excision repair and translesion synthesis, rewires these pathways, driving distinctive base-substitution mutational signatures of HR-defective tumors. Abasic sites, especially from methyl-cytosine metabolism, put replication forks at risk of breaking, amplifying the need for RAD51-mediated defense. Such redefinition of homologous recombination protein function as part of an anticipatory surveillance and protective system, rather than a repair-only module, bears important implications for understanding tumorigenesis, therapy resistance, and aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.